Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Early Hum Dev. 2020 May 22;147:105078. doi: 10.1016/j.earlhumdev.2020.105078

Table 4.

Multiple linear regression models with significant results using cytokine trends over time

Unadjusted β [95% CI] p-value R2 Adjusted β1 [95% CI] p-value R2 β1 [95% CI] p-value R2
NAPI MDV
  TNF-α −0.06 [−0.35, 0.23] 0.69 0.0026 −0.06 [−0.30, 0.19] 0.62 0.088 −0.09 [−0.86, 0.68] 0.82 0.16
  TNF-α*PMA −0.03 [−0.07, 0.01] 0.14
  TNF-α*sex 0.83 [0.07, 1.61] 0.032
  IL-1RA 0.22 [−0.30, 0.75] 0.4 0.037 0.14 [−0.40, 0.68] 0.6 0.10 0.89 [0.47, 1.30] <0.0005 0.23
  IL-1RA*PMA −0.04 [−0.07, −0.02] 0.002
  IL-1RA*sex −0.18 [−0.60, 0.22] 0.35
NAPI AO
  IL-6 −0.19 [−0.33, −0.05] 0.008 0.044 −0.23 [−0.37, −0.09] 0.002 0.091 0.06 [−0.76, 0.88] 0.88 0.12
  IL-6*PMA −0.01 [−0.03, 0.02] 0.67
  IL-6*sex −0.21 [−1.01, 0.59] 0.6
  IL-8 0.01 [−0.21, 0.23] 0.91 0.0002 0.03 [−0.19, 0.27] 0.78 0.032 0.74 [−0.23, 1.71] 0.13 0.14
  IL-8*PMA 0.01 [−0.04, 0.07] 0.68
  IL-8*sex −0.97 [−1.67, −0.29] 0.006

Note.

1

Adjusted for length of stay. NAPI, Neurobehavioral Assessment of the Preterm Infant; MDV, motor development and vigor; AO, alertness/orientation; TNF-α, tumor necrosis factor-alpha; IL-1RA, interleukin-1 receptor antagonist; PMA, post-menstrual age; β = standardized regression coefficient; CI, confidence interval. R2 = variance explained by model